[{"id":"cc0e252d-323c-463e-9f6b-bb8fa47915a5","acronym":"KEYNOTE-A87","url":"https://clinicaltrials.gov/study/NCT03565445","created_at":"2021-01-18T17:32:45.491Z","updated_at":"2025-02-25T16:08:02.730Z","phase":"Phase 1","brief_title":"A Study of ASP1948, Targeting an Immune Modulatory Receptor as a Single Agent and in Combination With a PD-l Inhibitor (Nivolumab or Pembrolizumab) in Subjects With Advanced Solid Tumors","source_id_and_acronym":"NCT03565445 - KEYNOTE-A87","lead_sponsor":"Astellas Pharma Global Development, Inc.","biomarkers":" EGFR • PD-L1 • ALK","pipe":" | ","alterations":" PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation","tags":["EGFR • PD-L1 • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e PD-L1 expression • EGFR mutation • PD-L1 overexpression • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e Keytruda (pembrolizumab) • Opdivo (nivolumab) • ASP1948"],"overall_status":"Completed","enrollment":" Enrollment 190","initiation":"Initiation: 07/02/2018","start_date":" 07/02/2018","primary_txt":" Primary completion: 03/27/2023","primary_completion_date":" 03/27/2023","study_txt":" Completion: 03/27/2023","study_completion_date":" 03/27/2023","last_update_posted":"2024-11-01"},{"id":"17c44e52-37cd-4c27-bc8b-09ad2ac7c326","acronym":"","url":"https://clinicaltrials.gov/study/NCT04094506","created_at":"2021-01-18T20:02:40.330Z","updated_at":"2024-07-02T16:35:54.165Z","phase":"Phase 1","brief_title":"Study of ASP1948, Targeting an Immune Modulatory Receptor, in Japanese Patients With Advanced Solid Tumors","source_id_and_acronym":"NCT04094506","lead_sponsor":"Astellas Pharma Inc","biomarkers":" EGFR • ALK","pipe":" | ","alterations":" EGFR mutation • ALK positive • ALK mutation","tags":["EGFR • ALK"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e EGFR mutation • ALK positive • ALK mutation"," \u003cb class=\"violet\"\u003e|\u003c/b\u003e ASP1948"],"overall_status":"Completed","enrollment":" Enrollment 9","initiation":"Initiation: 10/30/2019","start_date":" 10/30/2019","primary_txt":" Primary completion: 02/02/2022","primary_completion_date":" 02/02/2022","study_txt":" Completion: 02/02/2022","study_completion_date":" 02/02/2022","last_update_posted":"2023-03-03"}]